New contraindication for aliskiren-containing medications

Aliskiren-containing medications are contraindicated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with diabetes or renal impairment because of the risk of renal impairment, hypotension and hyperkalemia, the FDA recently warned.

Brand names of aliskiren-containing medications include Amturnide, Tekturna, Tekturna HCT, Tekamlo and Valturna (which will no longer be marketed after July 2012).